A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients

Autor: Joris Mallard, Elyse Hucteau, Laura Bender, Fabien Moinard‐Butot, Emma Rochelle, Lauréline Boutonnet, Antoine Grandperrin, Roland Schott, Carole Pflumio, Philippe Trensz, Michal Kalish‐Weindling, Anne‐Laure Charles, Bernard Gény, Fabrice Favret, Xavier Pivot, Thomas J. Hureau, Allan F. Pagano

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 1, Pp 292-305 (2024)

Abstract Background Breast cancer patients are commonly treated with sequential administrations of epirubicin–cyclophosphamide (EC) and paclitaxel (TAX). The chronic effect of this treatment induces skeletal muscle alterations, but the specific eff

Externí odkaz: https://doaj.org/article/389b65d381654c5b9b5742b279c46341

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy

Autor: Rudolph M. Navari, Bernardo L. Rapoport, Dan Powers, Sujata Arora, Rebecca Clark‐Snow

Publikováno v: Cancer Medicine, Vol 7, Iss 7, Pp 2943-2950 (2018)

Abstract Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy‐induced nausea and vomiting without antiemetic prophylaxis. While neurokinin‐1 receptor antagonists (NK‐1RAs) effectively prevent emesis, thei

Externí odkaz: https://doaj.org/article/2749e8759f9d4cb8a869026339ebdbea

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial

Autor: S. Dubey, J. D. Naik, S. Chan, Jørn Herrstedt, R. Davis, A. H. Jakobsen, J. von Pawel, Marianne Ewertz, Karin Jordan, Meinolf Karthaus, Yvonne Summers, G. Fox

Publikováno v: Herrstedt, J, Summers, Y, Jordan, K, von Pawel, J, Jakobsen, A H, Ewertz, M, Chan, S, Naik, J D, Karthaus, M, Dubey, S, Davis, R & Fox, G M 2019, ' Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy : a randomised, double-blind, placebo-controlled, dose-ranging trial ', Supportive Care in Cancer, vol. 27, no. 7, pp. 2699-2705 . https://doi.org/10.1007/s00520-018-4564-8

Purpose: Chemotherapy-induced nausea and vomiting (CINV) remain significant clinical problems, especially in the delayed phase (24–120 h after chemotherapy). Amisulpride is a dopamine D2/D3-receptor antagonist previously shown to be an effective in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e384e8507e3d1034b087c7e9b5cff64c
https://doi.org/10.1007/s00520-018-4564-8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.